Asunercept

BIOLOGICAL2 trials

Sponsors

Apogenix AG, Apogenix GmbH

Conditions

COVID-19COVID-19 Induced PneumoniaCovid19

Phase 2

Asunercept in Patients With Severe COVID-19

CompletedNCT04535674

Apogenix AGCovid19, COVID-19 Induced Pneumonia

Start: 2020-10-09End: 2021-12-21Updated: 2022-01-14

Phase 3

Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

TerminatedNCT05639192

Apogenix GmbHCOVID-19

Start: 2022-11-03End: 2023-08-18Updated: 2023-08-29

Related Papers

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial.

2024-10-241 citations